Artrya Raises A$75M Placement at A$2.05 to Fund U.S. Expansion
Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.
- A$75 million two-tranche placement at A$2.05 per share
- Up to A$5 million share purchase plan for existing shareholders
- Funds to accelerate U.S. commercial expansion and product development
- Supports rollout of Salix platform after FDA clearance of Coronary Plaque module
- Second tranche subject to shareholder approval in October 2025
Capital Raising to Fuel U.S. Expansion
Artrya Limited (ASX, AYA), an Australian medical technology company specialising in AI-driven cardiac diagnostics, has successfully secured A$75 million through a two-tranche placement priced at A$2.05 per share. This capital injection is complemented by the launch of a share purchase plan (SPP) of up to A$5 million, allowing existing eligible shareholders to participate at the same price point.
The funds raised are earmarked to accelerate the commercialisation and expansion of Artrya’s Salix platform in the United States, a critical market following the recent FDA clearance of its Salix Coronary Plaque (SCP) module. This regulatory milestone paves the way for broader adoption of the company’s AI-powered software that assists clinicians in near real-time assessment and management of coronary artery disease.
Strategic Priorities and Market Opportunity
Artrya plans to deploy the proceeds to support multiple facets of its U.S. strategy, including customer success initiatives, market access and reimbursement enablement, ongoing product development, and research efforts. Notably, the funds will also back the SAPPHIRE clinical study, which aims to generate robust evidence to further validate the platform’s clinical utility in assessing and treating patients at risk of coronary artery disease.
CEO John Konstantopoulos expressed confidence in the capital raising’s success, highlighting the strong institutional support and the company’s belief in Salix’s potential to address a significant global health challenge. The U.S. market, with its large hospital groups and complex reimbursement landscape, represents a major growth opportunity for Artrya’s innovative technology.
Placement Structure and Shareholder Participation
The initial tranche of the placement, approximately A$60 million, will be completed under existing placement capacity, while the second tranche of around A$15 million awaits shareholder approval at a general meeting scheduled for late October 2025. The SPP opens mid-September and closes in early October, offering eligible shareholders the chance to invest up to A$30,000 each.
The placement price reflects a modest discount to recent trading prices, balancing the need to attract new institutional investors while respecting existing shareholder value. Petra Capital acted as sole lead manager and bookrunner, underscoring the transaction’s strong market reception.
Looking Ahead
With this capital raise, Artrya is well-positioned to accelerate its U.S. commercial rollout and deepen clinical validation of its AI platform. The coming months will be critical as the company navigates shareholder approval processes, expands its footprint in major hospital groups, and advances the SAPPHIRE study. Success in these areas could significantly enhance Artrya’s standing in the competitive medical technology landscape focused on cardiovascular disease.
Bottom Line?
Artrya’s fresh capital injection sets the stage for a pivotal growth phase in the U.S., but execution risks and clinical validation remain key watchpoints.
Questions in the middle?
- Will shareholders approve the second tranche of the placement in October?
- How quickly can Artrya scale adoption of Salix across major U.S. hospital networks?
- What interim results can be expected from the SAPPHIRE clinical study?
